In the context of the intensification of changes in the pharmaceutical market, many pharmaceutical companies are currently "losing weight for the winter"
.
It is reported that recently, news of the sale and adjustment of R&D pipelines by pharmaceutical companies has been coming out
in the industry.
For example, some time ago, Hutchison Pharma announced that in response to the current challenging market conditions affecting the global biopharmaceutical industry, the company is actively making a strategic shift to focus on drugs that are cutting-edge in its internal development pipeline that have the potential to drive near-term value
.
According to the announcement, Hutchison's strategic adjustments mainly include: prioritizing its late-stage registration studies and regulatory approvals for the marketing of these drugs, especially the global registration of fruquintinib; Some early-stage research will no longer be prioritized for internal development, while certain other projects will consider external business opportunities; Seek potential partners to commercialize their drugs outside of China; Streamline your organization, redeploy key talent to support registration studies, regulatory filings, and more
.
In addition to announcing the adjustment of the layout of the R&D pipeline, innovative pharmaceutical companies have announced the closure or sale of industrialization bases
.
For example, on November 17, Jingfeng Pharmaceutical announced that according to the needs of the company's business and strategic development, its wholly-owned subsidiary Shanghai Jingfeng Pharmaceutical Co.
, Ltd.
intends to sell its real estate located in Lane 868, Puming Road, Pudong New Area, Shanghai, with a total construction area of 701.
63 square meters, for 120 million yuan
.
The property consists of 463.
55 square meters in Building 23, 017 (119.
04 square meters) on the 1st basement floor of No.
24, and 018 (119.
04 square meters)
on the 1st basement floor.
On November 15, Harbour Biopharma announced that it intends to sell WuXi Hyde, a subsidiary of Biologics Biologics Holdings, for RMB146 million
In addition, according to incomplete statistics, since October, at least 10 pharmaceutical companies, including Betta Pharmaceutical and Harbour Pharmaceutical, have announced the suspension or termination of new drug research and development projects
.
Among them, Betta Pharmaceutical said on the investor interactive platform on November 16 that the drug developed by the BPI-9016 project is a c-Met inhibitor, based on the existing clinical research data, the efficacy has not reached the expected target, and the company's development
has been suspended after comprehensive evaluation.
The industry believes that behind the frequent actions of pharmaceutical companies, it is the embodiment
of the acceleration of the transformation of the entire pharmaceutical market.
In addition, from the perspective of many innovative pharmaceutical companies shrinking their R&D pipelines, for innovative companies, how to screen the layout, optimize specific product pipelines, and input growth momentum for the company's development has become the top priority
of current development.
In the context that the screening of innovative pharmaceutical companies has become a key to success, especially in the context that most biotechnology companies have not yet achieved profitability, analysts expect that more and more pharmaceutical companies will re-examine the pipeline layout of various stages of innovative drug research and development, and join weight reduction actions such as cutting production bases and R&D pipelines to accelerate the exploration of precise breakthroughs
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
